Biochemotherapy of melanoma

Seminars in Oncology

Volumn 29, Issue 5, 2002, Pages 446-455

  Flaherty, Lawrence E ^a   Gadgeel, Shirish M ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; DACARBAZINE; INTERFERON; INTERLEUKIN 2; PACLITAXEL; TAMOXIFEN; TEMOZOLOMIDE; VINBLASTINE; VINCRISTINE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHRONOTHERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG PENETRATION; DRUG RESPONSE; HUMAN; IMMUNOMODULATION; MELANOMA; MENTAL DISEASE; METASTASIS; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL;

EID: 0037010052     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.35239     Document Type: Article

References (57)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer Statistics, 2001. CA Cancer J Clin 51:15-36, 2001
2. Lotze MT, Dallal RM, Kirkwood JM, et al: Cutaneous Melanoma, in Devita VT, Hellman S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology (ed 6). Philadelphia, PA, Lippincott Williams & Wilkins, 2001, pp 2012-2069
3. Middleton MR, Grob JJ, Aaronson N: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158-166, 2000
4. Margolin KA, Thompson JA, Clark J, et al: Temozolomide (TMZ) and whole brain irradiation (WB1) in melanoma (mel) metastatic to the brain (CNS): A phase II cytokine working group trial. Proc Am Soc Clin Oncol 20:359a, 1999 (abstr)
5. DelPrete SA, Maurer LH, O'Donnell J, et al: Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 68:1403-1405, 1984
6. McClay EF, Mastrangelo MJ, Bellet RE, et al: Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 71:465-469, 1987
7. Margolin KA, Liu PY, Flaherty LE, et al: Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: A Southwest Oncology Group study. Am J Clin Oncol 16:359-362, 1993
8. Chapman PB, Einhorn LH, Meyers ML, et al: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17:2745-2751, 1999
9. Kirkwood JM, Ernstoff MS: Cutaneous melanoma, in DeVita VT, Helman S, Rosenberg SA (eds): Biologic Therapy of Cancer. Philadelphia, PA, Lippincott, 1991, pp 247-274
10. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group rial EST 1684. J Clin Oncol 14:183-190, 1996
11. Kirkwood JM, Ibrahim JG, Sondak VK, et al: High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18: 2444-2458, 2000
12. Kirkwood JM: Studies of interferons in the therapy of melanoma. Semin Oncol 18:83-89, 1991
13. Legha S: Current therapy for melanoma. Semin Oncol 16:34-44, 1989
14. Atkins MB, Lotze MT, Dutcher JP, et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-2116, 1999
15. Atkins MB, Kunkel L, Sznol M, et al: High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update. Cancer J Sci Am 6:S11-14, 2000 (suppl 1)
16. West WH, Taver KW, Yannelli JR, et al: Constant infusion recombinant interleukin-2 in adoptive immunotherapy of adoptive cancer. N Engl J Med 316:898-905, 1987
17. Weiss GR, Margolin KA, Aronson KA, et al: A randomized phase II trial of continuous infusion interleukin-2 or bolus injection plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 10:275-281, 1992
18. Brunda MJ, Bellantoni D, Sulich V: In vivo anti-tumor activity of combinations of alpha-interferon and interleukin-2 in a murine model: Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer 40:365-371, 1987
19. Rosenberg SA, Lotze MT, Yang JC, et al: Combination therapy with interleukin-2 and alpha- interferon for the treatment of patients with advanced cancer. J Clin Oncol 7:1863-1874, 1989
20. Whitehead RP, Figlin R, Citron ML, et al: A phase II trial of concomitant human interleukin-2 and interferon alpha-2a in patients with disseminated malignant melanoma. J Immunother 13:117-121, 1993
21. Richards JM, Gilewski TA, Ramming K, et al: Effective chemotherapy for melanoma after treatment with interleukin-2. Cancer 69:427-429, 1992
22. Ehrke MJ, Mihich E, Berd D, et al: Effects of anticancer drugs on the immune system in humans. Semin Oncol 16:230-253, 1989
23. Mitchell MS: Combining chemotherapy with biological response modifiers in treatment of cancer. J Nad Cancer Inst 8:1445-1450, 1988
24. Chabot GG, Flaherty LE, Valdivieso M, et al: Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients. Cancer Chemother Pharmacol 27:157-160, 1990
25. Bajetta E, Di Leo A, Zampino MG, et al: Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 12:806-11, 1994
26. Falkson CI, Falkson G, Falkson HC: Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 9:1403-1408, 1991
27. Falkson CI, Ibrahim J, Kirkwood JM, et al: Phase III trial of dacarbazine versus dacarbazine with interferon a-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon a-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 16:1743-1751, 1998
28. Richner J, Joss RA, Goldhirsch A, et al: Phase II study of continuous subcutaneous interferon-alpha combined with cisplatinum in advanced malignant melanoma. Eur J Cancer 28:1044-1047, 1992
29. Margolin KA, Doroshow JH, Akman SA, et al: Phase II trial of cisplatinum and alpha-interferon in advanced malignant melanoma. J Clin Oncol 10:1574-1578, 1992
30. Margolin KA, Liu PY, Unger JM, et al: Phase II trial of biochemotherapy with interferon alfa, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: A Southwest Oncology Group trial. J Cancer Res Clin Oncol 125:292-296, 1999
31. Flaherty LE, Redman BG, Chabot GG, et al: A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma. Cancer 65:2471-2477, 1990
32. Stoter G, Shiloni E, Gundersen S, et al: Alternating recombinant interleukin-2 and dacarbazine in advanced melanoma. A multicenter phase II study. Cancer Treat Rev 16:59-63, 1989 (suppl A)
33. Papadopoulos NEJ, Howard JG, Murray JL, et al: Phase II DTIC and interleukin-2 (IL-2) trial for metastatic malignant melanoma. Proc Am Soc Clin Oncol 9:277, 1990 (abstr 1072)
34. Demchak PA, Mier JW, Robert NJ, et al: A phase II trial of interleukin-2 and high dose cisplatin in patients with metastatic melanoma. J Clin Oncol 9:1821-1830, 1991
35. Antoine EC, Benhammouda A, Bernard A, et al: Salpetriere hospital experience with biochemotherapy in metastatic melanoma. Cancer J Sci Am 3:S16-S21, 1997 (suppl)
36. Richards JM, Mehta N, Ramming K, et al: Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 10:1338-1343, 1992
37. Keilholz U, Conradt C, Legha S, et al: Results of interleukin-2 based treatment in advanced melanoma: A case record-based analysis in 631 patients. J Clin Oncol 16:2921-2929, 1998
38. Allen IE, Kupelnick B, Kumashiro M: Efficacy of interleukin-2 in the treatment of metastatic melanoma - Systemic review and metastasis-analysis. Cancer Therapeutics 1:168-173, 1998
39. Keilholz U, Schiebenbogen C, Tilgen W: Interferon-α and interleukin-2 in the treatment of metastatic melanoma. Cancer 72:607-614, 1993
40. O'Day SJ, Gammon G, Boasberg PD, et al: Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Oncol 17:2752-2761, 1999
41. Legha SS, Ring S, Eton O, et al: Development and results of biochemotherapy in metastatic melanoma: The University of Texas M.D. Anderson Cancer Center experience. Cancer J Sci Am 3:S9-S15, 1997.
42. McDermott DF, Mier JW, Lawrence DP, et al: A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. Clin Cancer Res 6:2201-2208, 2000
43. Flaherty LE, Robinson W, Redman BG, et al: A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer 71:3520-3525, 1993
44. Thompson JA, Gold PJ, Markowitz DR, et al: Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma. Cancer J Sci Am 3:S29-S34, 1997 (suppl)
45. Flaherty LE, Atkins M, Sosman J, et al: Randomized phase II trial of chemotherapy and outpatient biotherapy with interleukin-2 (IL-2) and interferon alpha (IFN) in metastatic malignant melanoma (MMM). Proc Am Soc Clin Oncol 18: 536a, 1999 (abstr)
46. Keilholz U, Goey SH, Punt CJ, et al: Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 15:2579-2588, 1997
47. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 17:968-975, 1999
48. Keilholz U, Cornelius JA, Punt CJA, et al: Dacarbazine, cisplatin and interferon alpha with or without interleukin-2 in advanced melanoma: Interim analysis of EORTC Trial 18951. Proc Am Soc Clin Oncol 18:530a, 1999 (abstr)
49. Eton O, Legha S, Bedikian A, et al: Phase III randomized trial of cisplatin, vinblastine and dacarbazine (CVD) plus interleukin-2 (IL2) and interferon-alpha-2b (INF) versus CVD in patients (Pts) with metastatic melanoma. Proc Am Soc Clin Oncol 19:552a, 2000 (abstr)
50. Ridolfi R, Romanini A, Labianca R, et al: Chemotherapy (CT) vs biochemotherapy (BioCT): A phase III trial in outpatients with advanced melanoma. Proc Am Soc Clin Oncol 19:552a, 2000 (abstr)
51. Buzaid AC, Bedikian A, Eton O, et al: Importance of major histologic response in melanoma patients (pts) with local regional metastases (LRM) receiving neoadjuvant biochemotherapy. Proc Am Soc Clin Oncol 16:503a, 1997 (abstr)
52. Dillman RO, Oladham RK, Barth NM, et al. Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: A National Biotherapy Study Group trial. J Natl Cancer Inst 82:1345-1349, 1990
53. Atzpodien J, Lopez Hanninen E, Kirchner H, et al: Chemoimmunotherapy of advanced malignant melanoma: Sequential administration of subcutaneous ionterleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer 31:876-881, 1995
54. Bernengo MG, Doveil GC, Bertero M, et al: Low-dose integrated chemoimmunohormonotherapy with cisplatin, subcutaneous interleukin-2, alpha-interferon and tamoxifen for advanced metastatic melanoma - A pilot study. Melanoma Research 6:257-265, 1996
55. Guida M, Latorre A, Mastria A, et al: Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma. Eur J Cancer 32:730-733, 1996
56. Kamanabrou, P, Straub C, Heinsch M, et al: Sequential biochemotherapy of INF-α/IL-2, cislatin (CDDP), dacarbazine (DTIC) and carmustine (BCNU), results of a monocenter phase II study in 109 patients with advanced metastatic malignant melanoma (MMM). Proc Am Soc Clin Oncol 18:530a, 1999 (abstr)
57. Dillman R, Soori G, Schulof R, et al: Cancer Biotherapy Research Group (CBRG) trial 94-11: Outpatient subcutaneous interleukin-2 (Proleukin) and interferon-2b (Intron A) with combination chemotherapy plus tamoxifen in the treatment of metastatic melanoma. Proc Am Soc Clin Oncol 18: 530a, 1999 (abstr)